Friday, July 14, 2017 News Recap Local New measures boost addiction treatment access in Victoria New efforts to expand treatment for opioid users in Victoria are putting addiction specialists in hospital emergency departments and supporting family doctors who provide opioid substitution therapy for patients. The initiatives by Island Health and the Victoria Divisions of Family Practice are intended to dovetail with the work of the South Island Ra...
HOPKINTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases, and certain cancers today announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining the use of Spring Bank's oral selective immunomodulator, SB 9200, co-administered with Gilea
3-drug mixture was nearly 100 percent effective in drug company trials WEDNESDAY, May 31, 2017 (HealthDay News) -- A pill that contains three powerful antiviral drugs might offer a cure for many hepatitis C patients who have failed other treatments, researchers report. The pill -- which contains the antiviral drugs sofosbuvir (Sovaldi), velpatasvir and voxilaprevir -- was nearly 100 percent effective in curing hepatitis C in patients whose disease retu...
California-headquartered Gilead Sciences has warned against the use of generic versions of its blockbuster Hepatitis C drugs procured by patients directly through “buyers clubs.” A disruptive phenomenon, dozens of buyers clubs have mushroomed in recent years that enable supply of generic lifesaving medicines to thousands of patients afflicted with the fatal liver ailment. In its latest May 9 regulatory filings in Form 10K at the US Securities Exchange Com
Friday, April 7, 2017 News Recap Canada Effective April 2017, Alberta Health has expanded access to treatments for hepatitis C in line with what the provinces of British Columbia, Ontario, Saskatchewan, and Québec have just done (Alberta expands drug coverage for hepatitis C patients). As Dr. Shafran, who is clearly worried about continued restrictions, says, “The funders have now opened the doors to let us treat people with mild liver disease … if ...
Decision enables price reductions and scale-up of treatment that leads to cure in 95% of cases Rio de Janeiro, 31 March, 2017 – Treatment for hepatitis C using the key drug sofosbuvir could be vastly scaled up in Brazil after the decision by the National Agency of Health Surveillance (Anvisa) to reject a key patent application on the drug marketed by pharmaceutical corporation Gilead. The decision could pave the way to enable generic competition in Brazil
Two drug combinations from Gilead and AbbVie that could improve treatment of chronic hepatitis C have been granted accelerated review in the EU. Gilead's application is for a three drug combination of NS5B polymerase inhibitor sofosbuvir, NS5A inhibitor velpatasvir and pan-genotypic protease inhibitor voxilaprevir – given over 12 weeks – that could achieve a cure for chronic hepatitis C virus (HCV) patients who have failed other regimens. The new direc
In a recent article in Forbes, MIT Sloan School of Management visiting scientist Mark Trusheim and co-author Peter B. Bach, a physician at Memorial Sloan Kettering Cancer Center in New York, propose a startling response to the prevalence of hepatitis C and the high cost of the leading therapy: The U.S. government should not just pay for the pills — they should buy their maker. The pharmaceutical company Gilead sells hepatitis C drugs that have 80 percent
Merck & Co on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni. The jury in Delaware reached the verdict following a nearly two-week trial, finding that a patent acquired by Merck in 2014 on hepatitis C treatments was valid. "The jury's verdict upholds patent protections that are essential to the development of new medica
If Approved, SOF/VEL/VOX Would Be the First Once-Daily Single Tablet Regimen Available as a Salvage Therapy for Patients Infected with HCV Genotype 1-6 Who Have Failed Prior Treatment with DAA Regimens Including NS5A Inhibitors FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 8, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, o